Dr Brian Wolpin reviews early clinical results evaluating daraxonrasib, a novel oral RAS(ON) multi-selective inhibitor, in combination with gemcitabine and nab-paclitaxel for first-line treatment of RAS-mutant metastatic pancreatic cancer.

This combination demonstrated encouraging preliminary efficacy in a disease where outcomes with standard chemotherapy remain limited.

By targeting active RAS signalling, daraxonrasib aims to enhance and prolong treatment responses when combined with chemotherapy.

The safety profile was consistent with known effects of each treatment component, with manageable toxicities and no treatment-related deaths reported.

Dose intensity was maintained for both daraxonrasib and chemotherapy, supporting the feasibility of this regimen.

Dr Wolpin says these findings support further development of daraxonrasib-based combinations, with a global phase III trial underway to better define its role in first-line metastatic pancreatic cancer.